{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033475","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.608431+00:00","generated_at":"2026-06-04T13:39:43.576623+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Design Therapeutics reports $281.8M cash, new FA drug product DT-216P2, IND cleared for DT-168, new HD program","bullets":["Net loss $11.8M in Q4 2023 and $66.9M for full year; cash & securities $281.8M funding 5-year runway.","New FA drug product DT-216P2 shows >10-fold improved PK and favorable injection site safety; GLP studies to complete by year-end 2024 for patient trials in 2025.","FDA cleared IND for DT-168 in FECD; Phase 1 to start in 2024; observational study of 200 patients underway.","New HD program targeting mutant HTT shows >50% selective reduction in brain striatum in preclinical studies.","DM1 GeneTAC molecules potently dial-down mutant DMPK, restore splicing; working toward development candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033475","json":"https://secwatch.observer/filing/0000950170-24-033475.json","markdown":"https://secwatch.observer/filing/0000950170-24-033475.md","text":"https://secwatch.observer/filing/0000950170-24-033475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024033475/0000950170-24-033475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024033475/dsgn-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:39:43.576623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03e96d66fe821ca5f451f7919213025bcf3774f6","claim":"Design Therapeutics, Inc. reported financial results for the three and twelve months ended December 31, 2023.","evidence_excerpt":"On March 19, 2024, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024033475/0000950170-24-033475-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}